{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:58:42Z","timestamp":1792796322695,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2018-2019"],"award-info":[{"award-number":["Ricerca Corrente 2018-2019"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["2020-2021"],"award-info":[{"award-number":["2020-2021"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["2022-2023"],"award-info":[{"award-number":["2022-2023"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR - M4C2-I1.3 Project PE_00000019 \"HEAL ITALIA\""],"award-info":[{"award-number":["PNRR - M4C2-I1.3 Project PE_00000019 \"HEAL ITALIA\""]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the fight against GBM, drug repurposing emerges as a viable and time-saving approach to explore new treatment options. Chlorpromazine, an old antipsychotic medication, has recently arisen as a promising candidate for repositioning in GBM therapy in addition to temozolomide, the first-line standard of care. We previously demonstrated the antitumor efficacy of chlorpromazine and its synergistic effects with temozolomide in suppressing GBM cell malignant features in vitro. This prompted us to accomplish a Phase II clinical trial to evaluate the efficacy and safety of adding chlorpromazine to temozolomide in GBM patients with unmethylated MGMT gene promoter. In this in vitro study, we investigate the potential role of chlorpromazine in overcoming temozolomide resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In our experimental set, we analyzed Connexin-43 expression at both the transcriptional and protein levels in control- and chlorpromazine-treated GBM cells. DNA damage and subsequent repair were assessed by immunofluorescence of \u03b3-H2AX and Reverse-Phase Protein microArrays in chlorpromazine treated GBM cell lines. To elucidate the relationship between DNA repair systems and chemoresistance, we analyzed a signature of DNA repair genes in GBM cells after treatment with chlorpromazine, temozolomide and Connexin-43 downregulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Chlorpromazine treatment significantly downregulated connexin-43 expression in GBM cells, consequently compromising connexin-dependent cellular resilience, and ultimately contributing to cell death. In line with this, we observed concordant post-translational modifications of molecular determinants involved in DNA damage and repair pathways. Our evaluation of DNA repair genes revealed that temozolomide elicited an increase, while chlorpromazine, as well as connexin-43 silencing, a decrease in DNA repair gene expression in GBM cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Chlorpromazine potentiates the cytotoxic effects of the alkylating agent temozolomide through a mechanism involving downregulation of Cx43 expression and disruption of the cell cycle arrest essential for DNA repair processes. This finding suggests that chlorpromazine may be a potential therapeutic strategy to overcome TMZ resistance in GBM cells by inhibiting their DNA repair mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-024-05501-3","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T04:01:52Z","timestamp":1721275312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways"],"prefix":"10.1186","volume":"22","author":[{"given":"Paola","family":"Matarrese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Signore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ascione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco G.","family":"Paggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3301-9421","authenticated-orcid":false,"given":"Claudia","family":"Abbruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"issue":"10","key":"5501_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"1","key":"5501_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13046-017-0642-x","volume":"36","author":"C Abbruzzese","year":"2017","unstructured":"Abbruzzese C, Matteoni S, Signore M, Cardone L, Nath K, Glickson JD, et al. Drug repurposing for the treatment of glioblastoma multiforme. J Exp Clin Cancer Res. 2017;36(1):169\u2013x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"24","key":"5501_CR3","doi-asserted-by":"publisher","first-page":"11499","DOI":"10.1158\/0008-5472.CAN-07-5312","volume":"67","author":"MM Alonso","year":"2007","unstructured":"Alonso MM, Gomez-Manzano C, Bekele BN, Yung WKA, Fueyo J. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007;67(24):11499\u2013504.","journal-title":"Cancer Res"},{"issue":"3","key":"5501_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/biomedicines7030069","volume":"7","author":"H Strobel","year":"2019","unstructured":"Strobel H, Baisch T, Fitzel R, Schilberg K, Siegelin MD, Karpel-Massler G, et al. Temozolomide and other alkylating agents in glioblastoma therapy. Biomedicines. 2019;7(3):69. https:\/\/doi.org\/10.3390\/biomedicines7030069.","journal-title":"Biomedicines"},{"issue":"10","key":"5501_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A, Gorlia T, Hamou M, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997\u20131003.","journal-title":"N Engl J Med"},{"issue":"3","key":"5501_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","volume":"3","author":"SY Lee","year":"2016","unstructured":"Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3(3):198\u2013210.","journal-title":"Genes Dis"},{"issue":"10","key":"5501_CR7","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1158\/1078-0432.CCR-07-1719","volume":"14","author":"JN Sarkaria","year":"2008","unstructured":"Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14(10):2900\u20138.","journal-title":"Clin Cancer Res"},{"issue":"7412","key":"5501_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nature11287","volume":"488","author":"J Chen","year":"2012","unstructured":"Chen J, Li Y, Yu T, McKay RM, Burns DK, Kernie SG, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488(7412):522\u20136.","journal-title":"Nature"},{"issue":"4","key":"5501_CR9","first-page":"271","volume":"10","author":"M Safari","year":"2015","unstructured":"Safari M, Khoshnevisan A. Cancer stem cells and chemoresistance in glioblastoma multiform: a review article. J Stem Cells. 2015;10(4):271\u201385.","journal-title":"J Stem Cells"},{"key":"5501_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105136","volume":"149","author":"JA Campos-Sandoval","year":"2021","unstructured":"Campos-Sandoval JA, G\u00f3mez-Garc\u00eda MC, Santos-Jim\u00e9nez JDL, Mat\u00e9s JM, Alonso FJ, M\u00e1rquez J. Antioxidant responses related to temozolomide resistance in glioblastoma. Neurochem Int. 2021;149: 105136.","journal-title":"Neurochem Int"},{"issue":"8","key":"5501_CR11","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3390\/cancers11081208","volume":"11","author":"JA Cockfield","year":"2019","unstructured":"Cockfield JA, Schafer ZT. Antioxidant defenses: a context-specific vulnerability of cancer cells. Cancers (Basel). 2019;11(8):1208. https:\/\/doi.org\/10.3390\/cancers11081208.","journal-title":"Cancers (Basel)"},{"issue":"5029","key":"5501_CR12","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/2091248a0","volume":"209","author":"WR Loewenstein","year":"1966","unstructured":"Loewenstein WR, Kanno Y. Intercellular communication and the control of tissue growth: lack of communication between cancer cells. Nature. 1966;209(5029):1248\u20139.","journal-title":"Nature"},{"issue":"4","key":"5501_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nrm1072","volume":"4","author":"DA Goodenough","year":"2003","unstructured":"Goodenough DA, Paul DL. Beyond the gap: functions of unpaired connexon channels. Nat Rev Mol Cell Biol. 2003;4(4):285\u201394.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7580","key":"5501_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature16071","volume":"528","author":"M Osswald","year":"2015","unstructured":"Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J, et al. Brain tumour cells interconnect to a functional and resistant network. Nature. 2015;528(7580):93\u20138.","journal-title":"Nature"},{"key":"5501_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.neuropharm.2013.05.002","volume":"75","author":"PR Gielen","year":"2013","unstructured":"Gielen PR, Aftab Q, Ma N, Chen VC, Hong X, Lozinsky S, et al. Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway. Neuropharmacology. 2013;75:539\u201348.","journal-title":"Neuropharmacology"},{"key":"5501_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.coph.2018.05.002","volume":"41","author":"CL Grek","year":"2018","unstructured":"Grek CL, Sheng Z, Naus CC, Sin WC, Gourdie RG, Ghatnekar GG. Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. Curr Opin Pharmacol. 2018;41:79\u201388.","journal-title":"Curr Opin Pharmacol"},{"issue":"8","key":"5501_CR17","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/cam4.730","volume":"5","author":"S Crespin","year":"2016","unstructured":"Crespin S, Fromont G, Wager M, Levillain P, Cronier L, Monvoisin A, et al. Expression of a gap junction protein, connexin43, in a large panel of human gliomas: new insights. Cancer Med. 2016;5(8):1742\u201352.","journal-title":"Cancer Med"},{"issue":"9","key":"5501_CR18","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/cgt.2011.38","volume":"18","author":"S Cottin","year":"2011","unstructured":"Cottin S, Gould PV, Cantin L, Caruso M. Gap junctions in human glioblastomas: implications for suicide gene therapy. Cancer Gene Ther. 2011;18(9):674\u201381.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"5501_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1158\/0008-5472.CAN-15-1286","volume":"76","author":"SF Murphy","year":"2016","unstructured":"Murphy SF, Varghese RT, Lamouille S, Guo S, Pridham KJ, Kanabur P, et al. Connexin 43 inhibition sensitizes chemoresistant glioblastoma cells to temozolomide. Cancer Res. 2016;76(1):139\u201349.","journal-title":"Cancer Res"},{"issue":"3","key":"5501_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1074\/jbc.M113.508390","volume":"289","author":"HT Le","year":"2014","unstructured":"Le HT, Sin WC, Lozinsky S, Bechberger J, Vega JL, Guo XQ, et al. Gap junction intercellular communication mediated by connexin43 in astrocytes is essential for their resistance to oxidative stress. J Biol Chem. 2014;289(3):1345\u201354.","journal-title":"J Biol Chem"},{"key":"5501_CR21","doi-asserted-by":"publisher","first-page":"3962173","DOI":"10.1155\/2017\/3962173","volume":"2017","author":"C Zhao","year":"2017","unstructured":"Zhao C, Fang J, Li C, Zhang M. Connexin43 and AMPK have essential role in resistance to oxidative stress induced necrosis. Biomed Res Int. 2017;2017:3962173.","journal-title":"Biomed Res Int"},{"issue":"11","key":"5501_CR22","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/neuonc\/noab186","volume":"23","author":"F Winkler","year":"2021","unstructured":"Winkler F. Silencing glioblastoma networks to make temozolomide more effective. Neuro Oncol. 2021;23(11):1807\u20139.","journal-title":"Neuro Oncol"},{"issue":"11","key":"5501_CR23","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.21037\/tcr-22-2318","volume":"11","author":"G Wang","year":"2022","unstructured":"Wang G, Wang Y, Wang S, Zhu L. Down-regulation of CX43 expression by miR-1 inhibits the proliferation and invasion of glioma cells. Transl Cancer Res. 2022;11(11):4126\u201336.","journal-title":"Transl Cancer Res"},{"issue":"4","key":"5501_CR24","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/bit.28313","volume":"120","author":"J Che","year":"2023","unstructured":"Che J, DePalma TJ, Sivakumar H, Mezache LS, Tallman MM, Venere M, et al. \u03b1CT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform. Biotechnol Bioeng. 2023;120(4):1108\u201319.","journal-title":"Biotechnol Bioeng"},{"issue":"1\u20132","key":"5501_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bbamem.2005.11.004","volume":"1719","author":"M Mesnil","year":"2005","unstructured":"Mesnil M, Crespin S, Avanzo J, Zaidan-Dagli M. Defective gap junctional intercellular communication in the carcinogenic process. Biochim Biophys Acta. 2005;1719(1\u20132):125\u201345.","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"5501_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/mc.20853","volume":"51","author":"P Strale","year":"2012","unstructured":"Strale P, Clarhaut J, Lamiche C, Cronier L, Mesnil M, Defamie N. Down-regulation of Connexin43 expression reveals the involvement of caveolin-1 containing lipid rafts in human U251 glioblastoma cell invasion. Mol Carcinog. 2012;51(11):845\u201360.","journal-title":"Mol Carcinog"},{"issue":"11","key":"5501_CR27","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1523\/JNEUROSCI.22-11-04302.2002","volume":"22","author":"JHC Lin","year":"2002","unstructured":"Lin JHC, Takano T, Cotrina ML, Arcuino G, Kang J, Liu S, et al. Connexin 43 enhances the adhesivity and mediates the invasion of malignant glioma cells. J Neurosci. 2002;22(11):4302\u201311.","journal-title":"J Neurosci"},{"issue":"1","key":"5501_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/cells9010117","volume":"9","author":"A Chepied","year":"2020","unstructured":"Chepied A, Daoud-Omar Z, Meunier-Balandre A, Laird DW, Mesnil M, Defamie N. Involvement of the gap junction protein, Connexin43, in the formation and function of invadopodia in the human U251 glioblastoma cell line. Cells. 2020;9(1):117. https:\/\/doi.org\/10.3390\/cells9010117.","journal-title":"Cells"},{"issue":"9","key":"5501_CR29","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/carcin\/bgt169","volume":"34","author":"SY Shin","year":"2013","unstructured":"Shin SY, Lee KS, Choi Y, Lim HJ, Lee HG, Lim Y, et al. The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt\/mTOR pathway in human U-87MG glioma cells. Carcinogenesis. 2013;34(9):2080\u20139.","journal-title":"Carcinogenesis"},{"issue":"1","key":"5501_CR30","doi-asserted-by":"publisher","first-page":"26-z","DOI":"10.1186\/s13046-020-1534-z","volume":"39","author":"C Abbruzzese","year":"2020","unstructured":"Abbruzzese C, Matteoni S, Persico M, Villani V, Paggi MG. Repurposing chlorpromazine in the treatment of glioblastoma multiforme: analysis of literature and forthcoming steps. J Exp Clin Cancer Res. 2020;39(1):26-z.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"5501_CR31","doi-asserted-by":"publisher","first-page":"347-w","DOI":"10.1186\/s13046-021-02144-w","volume":"40","author":"S Matteoni","year":"2021","unstructured":"Matteoni S, Matarrese P, Ascione B, Ricci-Vitiani L, Pallini R, Villani V, et al. Chlorpromazine induces cytotoxic autophagy in glioblastoma cells via endoplasmic reticulum stress and unfolded protein response. J Exp Clin Cancer Res. 2021;40(1):347-w.","journal-title":"J Exp Clin Cancer Res"},{"issue":"23","key":"5501_CR32","doi-asserted-by":"publisher","first-page":"37568","DOI":"10.18632\/oncotarget.17247","volume":"8","author":"CR Oliva","year":"2017","unstructured":"Oliva CR, Zhang W, Langford C, Suto MJ, Griguer CE. Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit. Oncotarget. 2017;8(23):37568\u201383.","journal-title":"Oncotarget"},{"issue":"12","key":"5501_CR33","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41419-023-06353-3","volume":"14","author":"C Abbruzzese","year":"2023","unstructured":"Abbruzzese C, Matteoni S, Matarrese P, Signore M, Ascione B, Iessi E, et al. Chlorpromazine affects glioblastoma bioenergetics by interfering with pyruvate kinase M2. Cell Death Dis. 2023;14(12):821\u20133.","journal-title":"Cell Death Dis"},{"issue":"7775","key":"5501_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41586-019-1563-y","volume":"573","author":"HS Venkatesh","year":"2019","unstructured":"Venkatesh HS, Morishita W, Geraghty AC, Silverbush D, Gillespie SM, Arzt M, et al. Electrical and synaptic integration of glioma into neural circuits. Nature. 2019;573(7775):539\u201345.","journal-title":"Nature"},{"issue":"7775","key":"5501_CR35","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-019-1564-x","volume":"573","author":"V Venkataramani","year":"2019","unstructured":"Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 2019;573(7775):532\u20138.","journal-title":"Nature"},{"issue":"11","key":"5501_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.635472","volume":"26","author":"S Matteoni","year":"2021","unstructured":"Matteoni S, Matarrese P, Ascione B, Buccarelli M, Ricci-Vitiani L, Pallini R, et al. Anticancer properties of the antipsychotic drug chlorpromazine and its synergism with temozolomide in restraining human glioblastoma proliferation in vitro. Front Oncol. 2021;26(11): 635472.","journal-title":"Front Oncol"},{"issue":"13","key":"5501_CR37","doi-asserted-by":"publisher","first-page":"1320710","DOI":"10.3389\/fonc.2023.1320710","volume":"14","author":"A Pace","year":"2023","unstructured":"Pace A, Lombardi G, Villani V, Benincasa D, Abbruzzese C, Cestonaro I, et al. Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial. Front Oncol. 2023;14(13):1320710.","journal-title":"Front Oncol"},{"issue":"6","key":"5501_CR38","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/ijc.33370","volume":"148","author":"P Visconti","year":"2021","unstructured":"Visconti P, Parodi F, Parodi B, Casarino L, Romano P, Buccarelli M, et al. Short tandem repeat profiling for the authentication of cancer stem-like cells. Int J Cancer. 2021;148(6):1489\u201398.","journal-title":"Int J Cancer"},{"issue":"7","key":"5501_CR39","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3390\/cells12071048","volume":"12","author":"P Matarrese","year":"2023","unstructured":"Matarrese P, Vona R, Ascione B, Cittadini C, Tocci A, Mileo AM. Tumor microenvironmental cytokines drive NSCLC cell aggressiveness and drug-resistance via YAP-mediated autophagy. Cells. 2023;12(7):1048. https:\/\/doi.org\/10.3390\/cells12071048.","journal-title":"Cells"},{"key":"5501_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/bs.mcb.2022.04.004","volume":"171","author":"M Signore","year":"2022","unstructured":"Signore M, Manganelli V. Reverse phase protein arrays in cancer stem cells. Methods Cell Biol. 2022;171:33\u201361.","journal-title":"Methods Cell Biol"},{"issue":"7","key":"5501_CR41","doi-asserted-by":"publisher","first-page":"636-z","DOI":"10.1038\/s41419-021-03909-z","volume":"12","author":"M Signore","year":"2021","unstructured":"Signore M, Alfonsi R, Federici G, Nanni S, Addario A, Bertuccini L, et al. Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer. Cell Death Dis. 2021;12(7):636-z.","journal-title":"Cell Death Dis"},{"issue":"5259","key":"5501_CR42","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/227680a0","volume":"227","author":"UK Laemmli","year":"1970","unstructured":"Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680\u20135.","journal-title":"Nature"},{"issue":"10","key":"5501_CR43","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1093\/neuonc\/noac105","volume":"24","author":"J Ding","year":"2022","unstructured":"Ding J, Li X, Khan S, Zhang C, Gao F, Sen S, et al. EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma. Neuro Oncol. 2022;24(10):1712\u201325.","journal-title":"Neuro Oncol"},{"key":"5501_CR44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","volume":"53","author":"Q Ma","year":"2013","unstructured":"Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401\u201326.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"5501_CR45","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2174\/1568009617666171002144228","volume":"18","author":"S Sajadimajd","year":"2018","unstructured":"Sajadimajd S, Khazaei M. Oxidative stress and cancer: the role of Nrf2. Curr Cancer Drug Targets. 2018;18(6):538\u201357.","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"5501_CR46","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.tcb.2020.03.002","volume":"30","author":"IS Harris","year":"2020","unstructured":"Harris IS, DeNicola GM. The complex interplay between antioxidants and ROS in cancer. Trends Cell Biol. 2020;30(6):440\u201351.","journal-title":"Trends Cell Biol"},{"issue":"13","key":"5501_CR47","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1128\/MCB.00248-10","volume":"30","author":"A Lau","year":"2010","unstructured":"Lau A, Wang X, Zhao F, Villeneuve NF, Wu T, Jiang T, et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol. 2010;30(13):3275\u201385.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"5501_CR48","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.pharep.2016.12.011","volume":"69","author":"V Krajka-Ku\u017aniak","year":"2017","unstructured":"Krajka-Ku\u017aniak V, Paluszczak J, Baer-Dubowska W. The Nrf2-ARE signaling pathway: an update on its regulation and possible role in cancer prevention and treatment. Pharmacol Rep. 2017;69(3):393\u2013402.","journal-title":"Pharmacol Rep"},{"issue":"11","key":"5501_CR49","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1089\/ars.2010.3221","volume":"13","author":"JD Hayes","year":"2010","unstructured":"Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal. 2010;13(11):1713\u201348.","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"5501_CR50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3892\/or.2021.7995","volume":"45","author":"Z Yang","year":"2021","unstructured":"Yang Z, Zhang L, Bi Q, Gan L, Wei M, Hong T, et al. Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide. Oncol Rep. 2021;45(4):44. https:\/\/doi.org\/10.3892\/or.2021.7995.","journal-title":"Oncol Rep"},{"issue":"11","key":"5501_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.629266","volume":"8","author":"L Li","year":"2021","unstructured":"Li L, Guan Y, Chen X, Yang J, Cheng Y. DNA repair pathways in cancer therapy and resistance. Front Pharmacol. 2021;8(11): 629266.","journal-title":"Front Pharmacol"},{"key":"5501_CR52","doi-asserted-by":"publisher","DOI":"10.4061\/2010\/920161","author":"M Podhorecka","year":"2010","unstructured":"Podhorecka M, Skladanowski A, Bozko P. H2AX phosphorylation: its role in DNA damage response and cancer therapy. J Nucleic Acids. 2010. https:\/\/doi.org\/10.4061\/2010\/920161.","journal-title":"J Nucleic Acids"},{"issue":"30","key":"5501_CR53","doi-asserted-by":"publisher","first-page":"29456","DOI":"10.18632\/oncotarget.4909","volume":"6","author":"SG Boccard","year":"2015","unstructured":"Boccard SG, Marand SV, Geraci S, Pycroft L, Berger FR, Pelletier LA. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study. Oncotarget. 2015;6(30):29456\u201368.","journal-title":"Oncotarget"},{"issue":"2","key":"5501_CR54","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/neuonc\/nov125","volume":"18","author":"S Agnihotri","year":"2016","unstructured":"Agnihotri S, Zadeh G. Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions. Neuro Oncol. 2016;18(2):160\u201372.","journal-title":"Neuro Oncol"},{"issue":"13","key":"5501_CR55","doi-asserted-by":"publisher","first-page":"5725","DOI":"10.1128\/MCB.25.13.5725-5737.2005","volume":"25","author":"K Katayama","year":"2005","unstructured":"Katayama K, Fujita N, Tsuruo T. Akt\/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2\/M transition. Mol Cell Biol. 2005;25(13):5725\u201337.","journal-title":"Mol Cell Biol"},{"issue":"7","key":"5501_CR56","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1128\/MCB.01611-06","volume":"27","author":"H Niida","year":"2007","unstructured":"Niida H, Katsuno Y, Banerjee B, Hande MP, Nakanishi M. Specific role of Chk1 phosphorylations in cell survival and checkpoint activation. Mol Cell Biol. 2007;27(7):2572\u201381.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"5501_CR57","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/ijc.28226","volume":"134","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Hunter T. Roles of Chk1 in cell biology and cancer therapy. Int J Cancer. 2014;134(5):1013\u201323.","journal-title":"Int J Cancer"},{"issue":"2","key":"5501_CR58","doi-asserted-by":"publisher","DOI":"10.1080\/23723548.2014.954507","volume":"1","author":"S Schmucker","year":"2014","unstructured":"Schmucker S, Sumara I. Molecular dynamics of PLK1 during mitosis. Mol Cell Oncol. 2014;1(2): e954507.","journal-title":"Mol Cell Oncol"},{"issue":"4","key":"5501_CR59","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.molcel.2013.10.006","volume":"52","author":"M Castellano-Pozo","year":"2013","unstructured":"Castellano-Pozo M, Santos-Pereira JM, Rond\u00f3n AG, Barroso S, And\u00fajar E, P\u00e9rez-Alegre M, et al. R loops are linked to histone H3 S10 phosphorylation and chromatin condensation. Mol Cell. 2013;52(4):583\u201390.","journal-title":"Mol Cell"},{"issue":"2","key":"5501_CR60","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1523\/JNEUROSCI.23-02-00430.2003","volume":"23","author":"JH Lin","year":"2003","unstructured":"Lin JH, Yang J, Liu S, Takano T, Wang X, Gao Q, et al. Connexin mediates gap junction-independent resistance to cellular injury. J Neurosci. 2003;23(2):430\u201341.","journal-title":"J Neurosci"},{"issue":"5","key":"5501_CR61","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/PPO.0000000000000540","volume":"27","author":"A Bonm","year":"2021","unstructured":"Bonm A, Kesari S. DNA damage response in glioblastoma: mechanism for treatment resistance and emerging therapeutic strategies. Cancer J. 2021;27(5):379\u201385.","journal-title":"Cancer J"},{"issue":"1","key":"5501_CR62","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1158\/0008-5472.CAN-16-1151","volume":"77","author":"ZD Nagel","year":"2017","unstructured":"Nagel ZD, Kitange GJ, Gupta SK, Joughin BA, Chaim IA, Mazzucato P, et al. DNA repair capacity in multiple pathways predicts chemoresistance in glioblastoma multiforme. Cancer Res. 2017;77(1):198\u2013206.","journal-title":"Cancer Res"},{"key":"5501_CR63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.mrrev.2016.05.005","volume":"769","author":"H Erasimus","year":"2016","unstructured":"Erasimus H, Gobin M, Niclou S, Van Dyck E. DNA repair mechanisms and their clinical impact in glioblastoma. Mutat Res Rev Mutat Res. 2016;769:19\u201335.","journal-title":"Mutat Res Rev Mutat Res"},{"issue":"6","key":"5501_CR64","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/cancers9060057","volume":"9","author":"L Annovazzi","year":"2017","unstructured":"Annovazzi L, Mellai M, Schiffer D. Chemotherapeutic drugs: DNA damage and repair in glioblastoma. Cancers (Basel). 2017;9(6):57. https:\/\/doi.org\/10.3390\/cancers9060057.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"5501_CR65","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11060-017-2626-2","volume":"135","author":"M Miyai","year":"2017","unstructured":"Miyai M, Tomita H, Soeda A, Yano H, Iwama T, Hara A. Current trends in mouse models of glioblastoma. J Neurooncol. 2017;135(3):423\u201332.","journal-title":"J Neurooncol"},{"issue":"3","key":"5501_CR66","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3390\/cells10030712","volume":"10","author":"WH Hicks","year":"2021","unstructured":"Hicks WH, Bird CE, Traylor JI, Shi DD, El Ahmadieh TY, Richardson TE, et al. Contemporary mouse models in glioma research. Cells. 2021;10(3):712. https:\/\/doi.org\/10.3390\/cells10030712.","journal-title":"Cells"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05501-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05501-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05501-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T04:06:57Z","timestamp":1721275617000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05501-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5501"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05501-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4376376\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"assertion":[{"value":"6 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"667"}}